Redefining Surrogate Endpoints for Enhanced Efficacy in Novel Immunotherapies

Time: 2:40 pm
day: Day 1 Track B PM


  • Building cell-free DNA (cfDNA) for tumor informed and tumor naive panel to monitor tumor mutational burden (TMB)
  • Identifying biochemical molecular responses and translating them using biopsy sequencing and ex vivo immunology assays
  • Identifying mechanisms of action to drive individual translational assays built for personalized medicine